Tirzepatide vs semaglutide: mechanism and outcomes
Two leading incretin therapies, one important mechanistic difference.
One receptor vs two
Semaglutide activates the GLP-1 receptor only (brands include Ozempic, Wegovy, Rybelsus). Tirzepatide activates both the GIP and GLP-1 receptors (Mounjaro, Zepbound). The added GIP activity is the main mechanistic difference and the leading hypothesis for tirzepatide's larger effects in head-to-head diabetes data.
SURPASS-2
In SURPASS-2, tirzepatide beat semaglutide 1 mg on A1c and weight in type 2 diabetes. The key caveat: the comparator was the 1 mg dose. Higher semaglutide doses (e.g., 2.4 mg for obesity) were not the comparator, so this isn't a verdict on every dose.
Comparing across trials
Cross-trial comparisons are imperfect, but tirzepatide's obesity trials (SURMOUNT-1: up to ~20.9% at 15 mg) generally show larger average weight reductions than semaglutide's obesity trials (STEP program: ~15% at 2.4 mg). Because populations and designs differ, treat such comparisons cautiously rather than as exact rankings.
More alike than different
Both are once-weekly injections (semaglutide also has an oral form) with gastrointestinal effects as the main side effects, both titrated slowly, and both associated with weight regain on stopping. Choice between them depends on individual factors, response, tolerability, availability and cost — a clinical decision.
Caveats
This compares the science, not a recommendation for any person. Compounded versions of either drug are not FDA-approved. Suitability is determined by a licensed clinician.
Why “stronger” isn't the only question
Even where data favor tirzepatide on average, “which is stronger” is not the only consideration in choosing between these drugs. Tolerability is individual — some people do better on one than the other for reasons not fully predictable in advance. Availability, formulation (semaglutide offers an oral option; both have injectables), insurance coverage for the branded products, and cost all matter, as does a clinician's familiarity and the specific goal (glucose control, weight, or a weight-related condition with its own evidence). Response also varies: a person who does not tolerate or respond well to one may do better on the other, so the “best” drug can only be known partly in advance. For compounded versions, neither is FDA-approved, and quality depends on the pharmacy regardless of which molecule. The sensible framing is that both are highly effective tools in the same class, and selection is an individualized clinical decision rather than a fixed ranking.
Primary sources
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab. 2018;18:3-14.
- U.S. Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Common questions
Is tirzepatide stronger than semaglutide?
In the head-to-head SURPASS-2 diabetes trial, tirzepatide produced greater A1c and weight reductions than semaglutide 1 mg. Cross-trial obesity comparisons also favor tirzepatide on average, but designs differ.
What's the main difference between them?
Semaglutide targets the GLP-1 receptor only; tirzepatide targets both GIP and GLP-1 receptors.
Do they have different side effects?
Both most commonly cause gastrointestinal effects and are titrated slowly; their side-effect profiles are broadly similar.